Close Menu

NEW YORK – Daiichi Sankyo said on Monday that the European Medicines Agency has accepted its marketing authorization application for trastuzumab deruxtecan (Daiichi Sankyo's Enhertu, DS-8201) for previously-treated HER2-positive breast cancer. The application has also been granted accelerated assessment by EMA's Committee for Medicinal Products for Human Use.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.